An RLT agent comprises two major components: a PSMA-targeted ligand (either a small molecule, e.g., PSMA-617 and PSMA-I&T, or a monoclonal antibody, e.g., J591) and a radioisotope aimed at destroying the PSMA-expressing tumour cells by emitting β-radiation (e.g., lutetium-177 [177Lu]) or α-radiation (e.g., actinium-225 [225Ac]) (51, 52). This evidence concerns the gene FOLH1 and neoplasm.